BioAffinity Technologies (BIAF) announced a significant surge in commercial sales of its CyPath Lung. The company said following a record-setting second quarter, the company’s third quarter started strong. Completed tests in July represent a 72% increase over the previous monthly average for the first six months of 2025. The upward trend reflects back-to-back record monthly sales in June and July. The company reaffirmed its forecast of three times year-over-year revenues for CyPath Lung.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIAF:
- bioAffinity’s CyPath® Lung Test Detects Early Cancer
- bioAffinity Technologies Approves Key Proposals at Annual Meeting
- bioAffinity’s CyPath® Lung Test Identifies Missed Tumor
- bioAffinity Technologies Secures Canadian Patent for Lung Cancer Detection
- BioAffinity Technologies awarded new Canadian patent for CyPath Lung